Research programme: small molecule therapeutics - Evotec SE/Novartis
Latest Information Update: 28 Aug 2021
At a glance
- Originator Evotec AG; Novartis
- Developer Evotec SE
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Pain
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in CNS-disorders in Germany
- 28 Aug 2021 No recent reports of development identified for preclinical development in Pain in Germany
- 29 Jul 2019 Preclinical development in CNS-disorders is ongoing in Germany (Evotec pipeline, July 2019)